Advertisement

Digestive Diseases and Sciences

, Volume 63, Issue 11, pp 2959–2968 | Cite as

Expression of DDB2 Protein in the Initiation, Progression, and Prognosis of Colorectal Cancer

  • Huaiwei Yang
  • Jingwei Liu
  • Jingjing Jing
  • Zeyang Wang
  • Yi Li
  • Kaihua Gou
  • Xue Feng
  • Yuan Yuan
  • Chengzhong Xing
Original Article

Abstract

Background

Damage-specific DNA binding protein 2 (DDB2) is implicated in the recognition of DNA damage and the initiation of nucleotide excision repair process. The aim of this study was to explore the role of DDB2 in the initiation, progression, and prognosis of colorectal cancer (CRC).

Methods

Totally tissues of 300 CRC and 300 adjacent, 267 colorectal adenoma (CRA) and 214 normal (NOR) were collected. The expression of DDB2 protein was detected by immunohistochemical staining.

Results

DDB2 protein was highly expressed in CRC and CRA compared with NOR (P < 0.001, respectively) in the dynamic sequence of NOR → CRA → CRC; CRC tissue demonstrated increased DDB2 expression compared with non-tumor adjacent tissues (P < 0.001). DDB2 expression was higher in T1–T2 than that in T3–T4 in CRC (P = 0.023); cloddy/nested CRC demonstrated increased DDB2 expression than infiltrative CRC (P = 0.007). Survival analysis showed that high DDB2 expression was associated with favorable survival in colon cancer (adjusted HR 0.20, 95% CI 0.06–0.72, P = 0.014) and female CRC patients (adjusted HR 0.27, 95% CI 0.08–0.92, P = 0.036).

Conclusion

DDB2 protein expression was associated with the initiation, progression, and prognosis of CRC, and might function as a tumor biomarker for the diagnosis and prognosis of CRC.

Keywords

DDB2 Expression Colorectal cancer 

Notes

Funding

This study is supported by grants from Public Welfare Foundation of Liaoning Province (No. 2015005002) and Fund for Scientific Research of The First Hospital of China Medical University (FHCMU-FSR).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

Ethical standard

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Supplementary material

10620_2018_5224_MOESM1_ESM.docx (18 kb)
Supplementary material 1 (DOCX 17 kb)

References

  1. 1.
    Sugasawa K. Regulation of damage recognition in mammalian global genomic nucleotide excision repair. Mutat Res. 2010;685:29–37.CrossRefGoogle Scholar
  2. 2.
    Alekseev S, Kool H, Rebel H, et al. Enhanced DDB2 expression protects mice from carcinogenic effects of chronic UV-B irradiation. Can Res. 2005;65:10298–10306.CrossRefGoogle Scholar
  3. 3.
    Feldberg RS, Grossman L. A DNA binding protein from human placenta specific for ultraviolet damaged DNA. Biochemistry. 1976;15:2402–2408.CrossRefGoogle Scholar
  4. 4.
    Ennen M, Klotz R, Touche N, et al. DDB2: a novel regulator of NF-kappaB and breast tumor invasion. Can Res. 2013;73:5040–5052.CrossRefGoogle Scholar
  5. 5.
    Gyorffy B, Lanczky A, Eklund AC, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1809 patients. Breast Cancer Res Treat. 2010;123:725–731.CrossRefGoogle Scholar
  6. 6.
    Roy N, Bommi PV, Bhat UG, et al. DDB2 suppresses epithelial-to-mesenchymal transition in colon cancer. Can Res. 2013;73:3771–3782.CrossRefGoogle Scholar
  7. 7.
    Han C, Zhao R, Liu X, et al. DDB2 suppresses tumorigenicity by limiting the cancer stem cell population in ovarian cancer. Mol Cancer Res. 2014;12:784–794.CrossRefGoogle Scholar
  8. 8.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefGoogle Scholar
  9. 9.
    Shiyanov P, Nag A, Raychaudhuri P. Cullin 4A associates with the UV-damaged DNA-binding protein DDB. J Biol Chem. 1999;274:35309–35312.CrossRefGoogle Scholar
  10. 10.
    Yoon T, Chakrabortty A, Franks R, Valli T, Kiyokawa H, Raychaudhuri P. Tumor-prone phenotype of the DDB2-deficient mice. Oncogene. 2005;24:469–478.CrossRefGoogle Scholar
  11. 11.
    Stoyanova T, Roy N, Bhattacharjee S, et al. p21 cooperates with DDB2 protein in suppression of ultraviolet ray-induced skin malignancies. J Biol Chem. 2012;287:3019–3028.CrossRefGoogle Scholar
  12. 12.
    Li Q, Yu JJ, Mu C, et al. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res. 2000;20:645–652.PubMedGoogle Scholar
  13. 13.
    Vogel U, Dybdahl M, Frentz G, Nexo BA. DNA repair capacity: inconsistency between effect of over-expression of five NER genes and the correlation to mRNA levels in primary lymphocytes. Mutat Res. 2000;461:197–210.CrossRefGoogle Scholar
  14. 14.
    Wei Q, Xu X, Cheng L, Legerski RJ, Ali-Osman F. Simultaneous amplification of four DNA repair genes and beta-actin in human lymphocytes by multiplex reverse transcriptase-PCR. Can Res. 1995;55:5025–5029.Google Scholar
  15. 15.
    Christmann M, Boisseau C, Kitzinger R, et al. Adaptive upregulation of DNA repair genes following benzo(a)pyrene diol epoxide protects against cell death at the expense of mutations. Nucl Acids Res. 2016;44:10727–10743.CrossRefGoogle Scholar
  16. 16.
    Stoyanova T, Roy N, Kopanja D, Raychaudhuri P, Bagchi S. DDB2 (damaged-DNA binding protein 2) in nucleotide excision repair and DNA damage response. Cell Cycle. 2009;8:4067–4071.CrossRefGoogle Scholar
  17. 17.
    Deng N, Liu JW, Sun LP, et al. Expression of XPG protein in the development, progression and prognosis of gastric cancer. PLoS ONE. 2014;9:e108704.CrossRefGoogle Scholar
  18. 18.
    Fu X, Hu J, Han HY, et al. High expression of XPA confers poor prognosis for nasopharyngeal carcinoma patients treated with platinum-based chemoradiotherapy. Oncotarget. 2015;6:28478–28490.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Gomez GV, de Oliveira C, Rinck-Junior JA, de Moraes AM, Lourenco GJ, Lima CS. XPC (A2920C), XPF (T30028C), TP53 (Arg72Pro), and GSTP1 (Ile105Val) polymorphisms in prognosis of cutaneous melanoma. Tumour Biol. 2016;37:3163–3171.CrossRefGoogle Scholar
  20. 20.
    Han JJ, Baek SK, Lee JJ, Kim GY, Kim SY, Lee SH. Combination of TRAP1 and ERCC1 expression predicts clinical outcomes in metastatic colorectal cancer treated with oxaliplatin/5-fluorouracil. Cancer Res Treat. 2014;46:55–64.CrossRefGoogle Scholar
  21. 21.
    Wang S, Wang J, Bai Y, et al. The genetic variations in DNA repair genes ERCC2 and XRCC1 were associated with the overall survival of advanced non-small-cell lung cancer patients. Cancer Med. 2016;5:2332–2342.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Tumor Etiology and Screening Department of Cancer Institute and General SurgeryThe First Affiliated Hospital of China Medical University, Key Laboratory of Cancer Etiology and Prevention (China Medical University), Liaoning Provincial Education DepartmentShenyang CityChina

Personalised recommendations